Survival determinants and treatment patterns in a European multi-center cohort of patients with nasopharyngeal carcinoma

Authors

  • Irina Maria Pușcaș Department of Pediatric Otorhinolaryngology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
  • Anda Gâta Department of Otorhinolaryngology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
  • Radu Alexandru Ilieș Faculty of Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
  • Paolo Boscolo Rizzo Department of Neurosciences, University of Padova, Treviso, Italy; Department of Medical, Surgical and Health Sciences, Section of Otolaryngology, University of Trieste, Italy
  • Marco Stellin Department of Neurosciences, University of Padova, Treviso, Italy
  • Vittorio Rampinelli Unit of Otorhinolaryngology - Head and Neck Surgery, Department of Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Italy
  • Davide Tomasini Radiation Oncology Department, ASST Spedali Civili, Brescia, Italy
  • Cesare Piazza Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, School of Medicine, University of Brescia, Italy
  • Daniele Borsetto Department of Otolaryngology - Head & Neck Surgery, Cambridge University Hospitals NHS Trust
  • Will Ince Department of Oncology, Cambridge University Hospitals NHS Trust
  • Carlos M. Chiesa-Estomba Department of Otolaryngology - Head and Neck Surgery, Donostia University Hospital (San Sebastián - Spain), Deusto University - Faculty of Medicine, Bilbao, Spain
  • Maria Landa-Garmendia Department of Otolaryngology - Head and Neck Surgery, Donostia University Hospital (San Sebastián - Spain), Deusto University - Faculty of Medicine, Bilbao, Spain
  • Pavol Surda Department of ENT Surgery, Guy’s and St Thomas University Hospital, London, UK
  • Eleanor Crossley Department of ENT Surgery, Guy’s and St Thomas University Hospital, London, UK
  • Alexandra Roman Department of Periodontology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca Romania
  • Andrei Constantin Ioanovici Department M2—Cmoplementary Functional Sciences, Medical Informatiacnsd Biostatistics, George Emil Palade UniversiMtye diocfin e, Pharmacy, Science, and Technology of Târgu Mureș, Romania
  • Vlad Alexandru Gâta Department of Surgical Oncology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
  • Alexandru Irimie Department of Surgical Oncology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
  • Silviu Albu Department oOft orhinolaryngology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

DOI:

https://doi.org/10.15386/mpr-2999

Keywords:

concurrent chemotherapy, chemoradiotherapy, nasopharyngeal carcinoma, multicentric European research, overall survival

Abstract

Background

Nasopharyngeal carcinoma (NPC) is a distinct head and neck malignancy characterized by marked geographic and ethnic variability, with most studies originating from endemic Asian regions. However, the disease also occurs in non-endemic populations, where prognostic factors and treatment outcomes may differ. This study aimed to evaluate overall survival (OS) in a European multi-institutional cohort of patients with NPC and to assess the impact of disease stage and chemotherapy exposure on survival outcomes.

Methods

A retrospective multicenter study was conducted including patients diagnosed with NPC in six oncology centers across Romania, Italy, Spain, and the United Kingdom. Eligible patients had histologically confirmed NPC and a minimum follow-up of five years. Clinical, demographic, staging, and treatment data were collected from medical records. OS was estimated using the Kaplan–Meier method and compared using the log-rank test. Univariable and multivariable Cox proportional hazards regression analyses were performed to identify prognostic factors.

Results

A total of 416 patients were included, with a mean age of 48.2 years and a predominance of males (68%). Most patients presented with advanced-stage disease (83.7%). Concurrent chemotherapy was administered in 73.3% of cases. Median survival was 204 months in patients receiving chemotherapy and 187 months in those without chemotherapy, with no significant difference between groups (p = 0.85). Chemotherapy exposure was not independently associated with OS in multivariable analysis. Increasing age was identified as an independent prognostic factor associated with higher mortality risk (HR 1.03 per year, p < 0.001).

Conclusions

In this European multicenter cohort, OS in NPC patients was primarily influenced by age, as demonstrated by independent multivariable Cox regression (HR 1.03 per year, p < 0.001), while concurrent chemotherapy was not independently associated with improved survival. Disease stage was used as a stratification variable in the multivariable model to account for non-proportional hazards; accordingly, no hazard ratio for stage is estimated. Kaplan–Meier analysis suggested higher survival probabilities in early-stage disease, though this difference did not reach statistical significance (log-rank p = 0.099). Further prospective studies are needed to clarify the role of systemic therapy in non-endemic populations.

 

Downloads

Published

2026-07-02

Issue

Section

Original Research

How to Cite

1.
Survival determinants and treatment patterns in a European multi-center cohort of patients with nasopharyngeal carcinoma. Med Pharm Rep [Internet]. 2026 Jul. 2 [cited 2026 Nov. 19];99(4):335-44. Available from: https://medpharmareports.com/index.php/mpr/article/view/2999